Research progress on CD8+T cell dysfunction in chronic hepatitis B virus infection.
- Author:
Nan ZHANG
1
;
Chuanhai LI
2
;
Rongjie ZHAO
1
;
Liwen ZHANG
1
;
Qing OUYANG
1
;
Liyun ZOU
1
;
Ji ZHANG
3
,
4
Author Information
1. Institute of Immunology, Army Medical University, Chongqing 400038, China.
2. Department of Thoracic Surgery, The No. 960 Hospital of PLA, Jinan 250031,China.
3. Institute of Immunology, Army Medical University, Chongqing 400038, China. *Corresponding author, E-mail: zhangji.ljia@
4. com.
- Publication Type:English Abstract
- MeSH:
Humans;
Hepatitis B, Chronic/virology*;
CD8-Positive T-Lymphocytes/immunology*;
Hepatitis B virus/physiology*;
Animals;
Transforming Growth Factor beta/immunology*
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(5):456-460
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV)-specific CD8+ T cells play a central role in controlling HBV infection; however, their function is impaired during chronic HBV infection, manifesting as a state of dysfunction. Recent studies have revealed that CD8+ T cell dysfunction in chronic HBV infection differs from the classical exhaustion observed in other viral infections or tumors. In 2024, several pivotal studies further elucidated novel mechanisms underlying CD8+ T cell dysfunction in chronic HBV infection and identified new therapeutic targets, including 4-1BB and transforming growth factor-beta (TGF-β). This review, while elucidating the dysfunction of CD8+ T cells in chronic HBV infection and its underlying mechanisms, focuses on summarizing the key findings from these latest studies and explores their translational value and clinical significance.
